Eli Lilly's CEO announced strong early adoption for its new oral GLP-1 drug, Foundayo, capturing one-third of new oral GLP-1 patients and 70% of new senior GLP-1 patients following Medicare coverage. This indicates significant market penetration and growth potential for Lilly's obesity drug portfolio, particularly with the new manufacturing expansion.
Eli Lilly's CEO, Dave Ricks, revealed that their new oral GLP-1 drug, Foundayo, is capturing a significant one-third of new oral GLP-1 patients, and their overall GLP-1 treatments are used by 70% of new senior patients following Medicare's expanded coverage. This indicates robust demand and successful market entry for Lilly's obesity drugs, especially Foundayo, which offers a convenient oral option. The company is also expanding manufacturing with a new $6.5 billion facility for Foundayo and other APIs, signaling long-term commitment and capacity for global expansion. This news is a strong positive for LLY, reinforcing its leadership in the lucrative GLP-1 market and potentially putting pressure on competitors like Novo Nordisk (NVO) as the battle for market share intensifies.